STOCK TITAN

Shareholder plans sale of 135,117 RPRX shares (NASDAQ: RPRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A shareholder in RPRX has filed a Form 144 notice to sell up to 135,117 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $5,805,977.49. The notice lists 427,247,489 shares outstanding and targets an approximate sale date of February 3, 2026 on NASD.

The shares to be sold were acquired from the issuer in a private transaction on June 16, 2020 and as compensation via performance awards on February 12, 2020. The filing also details multiple past three‑month sales by entities TPC RP EPA1 LLC and TPC RP 2021 LLC, including individual transactions of up to 69,665 shares for $2,938,636.90 in gross proceeds.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the RPRX Form 144 filing disclose?

The Form 144 for RPRX discloses a planned sale of restricted or control shares by a shareholder. It outlines the number of shares, their market value, acquisition details, and recent prior sales, giving investors insight into upcoming potential selling activity.

How many RPRX shares are planned for sale in this Form 144?

The filing indicates a planned sale of 135,117 shares of RPRX common stock. These shares have an aggregate market value of $5,805,977.49, based on the prices used in the notice, and are expected to be sold around February 3, 2026.

Which broker will execute the planned RPRX share sale?

The planned sale of RPRX shares is listed to be executed through Goldman Sachs & Co. LLC. The broker’s address is given as 200 West Street, New York, NY 10282, and the shares are expected to trade on NASD.

How were the RPRX shares in this Form 144 originally acquired?

The RPRX shares were acquired from the issuer in two ways. 127,835 shares came from a private transaction on June 16, 2020, and 7,282 shares were granted as compensation via performance awards on February 12, 2020.

What past three-month RPRX share sales are reported in the filing?

The filing lists multiple sales of RPRX common stock over the past three months by TPC RP EPA1 LLC and TPC RP 2021 LLC. Individual transactions include amounts up to 69,665 shares with gross proceeds as high as $2,938,636.90.

How many RPRX shares are outstanding according to this notice?

The notice states that 427,247,489 shares of RPRX common stock are outstanding. This figure provides a baseline context for understanding the relative size of the planned 135,117-share sale disclosed in the Form 144 filing.
Royalty Pharma Plc

NASDAQ:RPRX

RPRX Rankings

RPRX Latest News

RPRX Latest SEC Filings

RPRX Stock Data

18.10B
387.98M
8.74%
82.44%
3.85%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK